B
BCRX
Biocryst Pharmaceuticals Inc
9.87
+0.04+0.41%After Hours: 9.95 +0.08 +0.81%18:12 08/27 EDT
OPEN/PREV CLOSE9.75/9.83
TODAY RANGE9.55-9.92
VOL2.48M
MARKET CAP2.52B
52 WEEK RANGE6.00-11.22
AVG VOL (3M)4.32M
% TURNOVER0.97%
TURNOVER--
P/E (TTM)-6.5625
% RANGE3.75%
EPS(TTM)-1.5040
P/E(FORWARD)-4.2993
P/B-5.5459
BVPS-1.7797
DIVIDEND--
P/S2.404
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.33B
SHARES OUTSTANDING255.54M
NEXT EARNINGS11/02-11/06
FREE FLOAT236.31M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·14h ago
How Investors Are Reacting To BioCryst (BCRX) Winning Japan’s First Oral Pediatric HAE Approval
Benzinga·1d ago
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Simply Wall St·4d ago
BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?
TipRanks·08/17 00:26
BioCryst Earnings Call Highlights Growth And Discipline
Simply Wall St·08/15 05:23
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares
Simply Wall St·08/11 16:26
BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance
Simply Wall St·08/07 07:32
How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors
Dow Jones·08/06 17:18
BioCryst Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones·08/06 17:18
BioCryst Pharmaceuticals Price Target Cut to $13.00/Share From $14.00 by RBC Capital
Benzinga·08/06 17:07
RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13
Dow Jones·08/06 16:00
BioCryst Pharmaceuticals Price Target Cut to $20.00/Share From $21.00 by Wedbush
Dow Jones·08/06 16:00
BioCryst Pharmaceuticals Is Maintained at Outperform by Wedbush
Same Industry
Name/Symbol
Change%
Price